Core Viewpoint - Inspire Medical Systems, Inc. has announced an accelerated share repurchase transaction of $75 million as part of a $150 million share repurchase program, reflecting confidence in its long-term growth potential and commitment to enhancing shareholder value [1][2]. Group 1: Share Repurchase Program - The company has entered into an accelerated share repurchase (ASR) transaction with Goldman Sachs to repurchase $75 million of its common stock [1]. - This ASR is part of a previously announced $150 million share repurchase program authorized by the Board of Directors [1]. - The ASR transaction is expected to conclude in the first quarter of 2025 [2]. Group 2: Management's Perspective - The Chairman and CEO of Inspire expressed confidence in the company's long-term growth potential, supported by strong revenue and earnings growth, and future cash generation expectations [2]. - The company aims to balance future growth investments with shareholder value enhancement through a disciplined capital allocation strategy, which may include opportunistic share repurchases [2]. Group 3: Share Repurchase Considerations - In deciding the capital allocation for share repurchases, the company evaluates its historical and expected business performance, cash and liquidity position, and market conditions [3]. - The timing, manner, price, and amount of repurchases are at the company's discretion, and the program may be modified or discontinued at any time [3]. - The share repurchase program is set to expire on August 5, 2026, unless terminated or extended by the Board [3]. Group 4: Company Overview - Inspire Medical Systems focuses on developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea [4]. - The company's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [4].

Inspire Medical Systems, Inc. (INSP) delivered an earnings per share (EPS) of 60 cents in third-quarter 2024 against the year-ago period’s loss of 29 cents per share. The metric surpassed the Zacks Consensus Estimate by a huge 900%.INSP’s Revenues in DetailInspire Medical registered revenues of $203.2 million in the third quarter, up 32.5% year over year. The figure beat the Zacks Consensus Estimate by 2.8%.Per management, the top-line growth was driven by increased market penetration in existing centers, e ...

For the quarter ended September 2024, Inspire Medical Systems (INSP) reported revenue of $203.19 million, up 32.5% over the same period last year. EPS came in at $0.60, compared to -$0.29 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $197.65 million, representing a surprise of +2.81%. The company delivered an EPS surprise of +900.00%, with the consensus EPS estimate being $0.06.While investors closely watch year-over-year changes in headline numbers -- revenue and ...

Inspire Medical Systems (INSP) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 900%. A quarter ago, it was expected that this maker of devices for treating obstructive sleep apnea would post a loss of $0.14 per share when it actually produced earnings of $0.32, delivering a surprise of 32 ...

Core Insights - Inspire Medical Systems reported a strong financial performance for Q3 2024, with a revenue of $203.2 million, marking a 33% increase year-over-year [2][3] - The company achieved a gross margin of 84.1% and generated an operating income of $14.3 million, a significant turnaround from an operating loss of $13.5 million in the prior year [4][5] - Inspire is increasing its full-year revenue guidance to between $793 million and $798 million, reflecting a growth of 27% to 28% over 2023 [6][7] Recent Business Highlights - Revenue for Q3 2024 was $203.2 million, a 33% increase from $153.3 million in Q3 2023 [3] - U.S. revenue for the quarter was $195.8 million, also a 33% increase compared to the prior year [3] - The company activated 66 new U.S. centers in Q3 2024, bringing the total to 1,371 centers [2] - Inspire created 13 new U.S. sales territories, increasing the total to 323 [2] - The Inspire V neurostimulation system received FDA approval [2] Financial Performance - Gross margin remained stable at 84.1% for both Q3 2024 and Q3 2023 [3] - Operating expenses increased to $156.5 million, a 10% rise from $142.4 million in the prior year [4] - Net income for Q3 2024 was $18.5 million, compared to a net loss of $8.5 million in Q3 2023 [5] - Diluted earnings per share for Q3 2024 were $0.60, up from a diluted net loss of $0.29 per share in the prior year [5] Full Year Guidance - The company raised its full-year 2024 revenue guidance to $793 million to $798 million, up from the previous guidance of $788 million to $798 million [6] - Full-year earnings per share guidance was increased to $1.20 to $1.40, compared to the prior range of $0.60 to $0.80 [7] - Inspire maintains its guidance for opening 52 to 56 new U.S. medical centers per quarter [7]

Core Viewpoint - Inspire Medical Systems (INSP) is expected to report a quarterly earnings per share (EPS) of $0.06, reflecting a year-over-year increase of 120.7%, with revenues projected at $197.65 million, a 28.9% increase compared to the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not reassessed their initial estimates during this period [2]. - Revisions to earnings projections are crucial for predicting investor behavior regarding the stock, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price performance [3]. Revenue Projections - Analysts estimate that 'Geographic Revenue - United States' will reach $191.01 million, representing a year-over-year increase of 29.5% [5]. - The consensus estimate for 'Geographic Revenue - All other countries' is $6.68 million, indicating a year-over-year increase of 15.5% [5]. Medical Centers and Sales Territories - Analysts predict that 'New U.S. Medical Centers' will total 53, down from 62 in the previous year [5]. - The total number of 'U.S. Medical Centers' is expected to reach 1,369, up from 1,107 in the same quarter last year [6]. - 'New U.S. sales territories' are projected to remain at 13, while 'Total U.S. sales territories' are expected to increase to 323 from 274 year-over-year [6]. Stock Performance - Shares of Inspire have decreased by 4.9% over the past month, contrasting with a 1.8% increase in the Zacks S&P 500 composite [7]. - With a Zacks Rank of 2 (Buy), INSP is anticipated to outperform the overall market in the near future [7].

Industry Overview - The Medical Info Systems industry is rapidly expanding, driven by technological advancements and increasing global demand for new-generation products, improving patient care and connectivity between healthcare providers and insurance plans [1] - The industry comprises companies that develop and market healthcare information systems, offering software and hardware solutions for secure access to real-time clinical, administrative, and financial data [4] Market Trends - The use of artificial intelligence (AI) in the medical device market is projected to grow at a CAGR of 44.4% from 2024 to 2028, driven by the need for healthcare systems to reduce time and costs while improving detection capabilities [2] - The global Smart Healthcare Products market was valued at $145.9 billion in 2023 and is expected to reach $485.71 billion by 2032, growing at a CAGR of 12.78% [5] - Remote patient monitoring and telehealth services are experiencing significant growth due to increased awareness of continuous patient monitoring devices [5] Company Highlights - Inspire Medical Systems (INSP) focuses on innovative solutions for obstructive sleep apnea and is expanding its sales and marketing efforts in the U.S. and Europe, with a projected earnings growth of 204.2% for 2024 [15][16] - 10x Genomics (TXG) develops products for analyzing biological systems and is expected to see an 18.7% improvement in earnings for 2024 [12][13] - Omnicell, Inc. (OMCL) is targeting revenue growth of $1.9 billion to $2 billion by 2025, representing a CAGR of 14%-15% from 2021 to 2025 [14] Financial Performance - The Medical Info Systems industry has gained 13.7% over the past year, underperforming the Zacks Medical sector's growth of 15.5% and the S&P 500's rise of 39.4% [10] - The industry is currently trading at a forward price-to-sales (P/S) ratio of 1.52X, compared to the S&P 500's 5.12X and the sector's 3.02X [11] Cybersecurity Concerns - As healthcare becomes more interconnected, cybersecurity is a primary concern, with increasing vulnerabilities in electronic medical devices and systems [7]

Inspire Medical Systems (INSP) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. Individual ...

Core Viewpoint - Inspire Medical Systems, Inc. will release its financial results for Q3 2024 on November 4, 2024, after market close, followed by a conference call to discuss the results and recent business developments [1]. Financial Results Announcement - The financial results for Q3 2024 will be announced after the close of trading on November 4, 2024 [1]. - A conference call will be held at 5:00 p.m. Eastern Time on the same day to discuss the results [1]. Conference Call Details - A webcast of the conference call will be available on the Investor Relations page of Inspire's website [2]. - For those wishing to ask questions, registration is required, and an email with dial-in details will be sent after registration [3]. - It is recommended to register at least 10 minutes before the call starts to ensure connection [3]. Replay Information - A replay of the conference call will be available on the Company's Investor Relations website approximately two hours after the event and will be archived for two weeks [4]. Company Overview - Inspire Medical Systems focuses on developing and commercializing innovative, minimally invasive solutions for obstructive sleep apnea [5]. - The company's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [5].

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? T ...